Overview
Jonathan Mobley is an Urologist in Fairfax, Virginia. Dr. Mobley is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are UPJ Obstruction, Obstructive Uropathy, Bilateral Hydronephrosis, Ureteroscopy, and Lithotripsy. Dr. Mobley is currently accepting new patients.
His clinical research consists of co-authoring 10 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Renal Cell Carcinoma (RCC).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- POS
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- MEDICARE MAPD
- OTHER MEDICARE
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- PPO
- HMO
- POS
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
3650 Joseph Siewick Dr, Suite 106, Fairfax, VA 22033
3300 Gallows Rd, Falls Church, VA 22042
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Mark Ball is a Plastic Surgeon and an Urologist in Bethesda, Maryland. Dr. Ball is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Von Hippel-Lindau (VHL) Syndrome, Renal Cell Carcinoma (RCC), Renal Oncocytoma, Nephrectomy, and Prostatectomy.
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.
University Of Maryland Surgical Associates PA
Michael Phelan is an Urologist and a General Surgeon in Baltimore, Maryland. Dr. Phelan is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery. Dr. Phelan is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Bilateral HydronephrosisDr. Mobley isAdvanced. Learn about Bilateral Hydronephrosis.
- BoilsDr. Mobley isAdvanced. Learn about Boils.
- CarbuncleDr. Mobley isAdvanced. Learn about Carbuncle.
- Familial Prostate CancerDr. Mobley isAdvanced. Learn about Familial Prostate Cancer.
- FolliculitisDr. Mobley isAdvanced. Learn about Folliculitis.
- HydronephrosisDr. Mobley isAdvanced. Learn about Hydronephrosis.
- Experienced
- AcrospiromaDr. Mobley isExperienced. Learn about Acrospiroma.
- Bladder CancerDr. Mobley isExperienced. Learn about Bladder Cancer.
- Bladder Outlet ObstructionDr. Mobley isExperienced. Learn about Bladder Outlet Obstruction.
- Bladder StonesDr. Mobley isExperienced. Learn about Bladder Stones.
- Chromophobe Renal Cell CarcinomaDr. Mobley isExperienced. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Mobley isExperienced. Learn about Clear Cell Sarcoma.